March 06, 2023 — 06:14 am EST

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - Adaptimmune Therapeutics plc (ADAP) and TCR² Therapeutics Inc. (TCRR) have entered into a definitive agreement under which Adaptimmune will combine with TCR² in an all-stock deal. TCR² stockholders will receive 1.5117 Adaptimmune ADS for each TCR² share. Adaptimmune shareholders will own approximately 75% of the combined company and TCR²  stockholders will own approximately 25% of the combined company. 
It is anticipated that the combined company's cash runway will extend into 2026. The combined company is expected to continue to trade on the Nasdaq Stock Market under the symbol ADAP. 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.